Where are we going with ulcerative colitis management?

Selwyn Odes

Research output: Contribution to journalReview articlepeer-review

Abstract

Impressive progress has been made in the treatment of ulcerative colitis. Corticosteroids are nowadays limited to short-term use. The mainstay of current therapy consists of the immunosuppressive drugs (largely thiopurine analogs) and the biologics, often in combination. The calcineurin inhibitors are still in use for acute severe colitis in many centers. However, gastroenterologists can now choose between calcineurin inhibitors and biologics for administration to patients with fulminant disease, although the criteria for selection are not yet resolved. Given the success rates of current therapies, it is obvious that new and better drug development is required if surgery is to disappear from the armamentarium of treatments.

Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalExpert Opinion on Emerging Drugs
Volume18
Issue number1
DOIs
StatePublished - 1 Mar 2013
Externally publishedYes

Keywords

  • Biologics
  • Immunosuppression
  • Therapy
  • Ulcerative colitis

Fingerprint

Dive into the research topics of 'Where are we going with ulcerative colitis management?'. Together they form a unique fingerprint.

Cite this